CNTB Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.610

Open

3.610

VWAP

3.01

Vol

1.06M

Mkt Cap

192.87M

Low

2.580

Amount

3.18M

EV/EBITDA(TTM)

--

Total Shares

55.90M

EV

138.09M

EV/OCF(TTM)

--

P/S(TTM)

251.14

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Show More

Events Timeline

(ET)

2026-03-30

07:30:00

Connect Biopharma Announces 52-Week Eczema Study Results

2026-01-12 (ET)

2026-01-12

08:30:00

Connect Biopharma Highlights 2026 Priorities and New Mechanism Data for Rademikibart

2025-12-01 (ET)

2025-12-01

08:50:00

Lake Street Initiates Buy Rating on Connect Biopharma with $9 Price Target

2025-11-12 (ET)

2025-11-12

09:03:11

Connect Biopharma Announces Q3 Earnings Per Share of 31 Cents, Exceeding Consensus Estimate of 24 Cents

2025-09-29 (ET)

2025-09-29

09:15:22

Connect Biopharma showcases rademikibart data at ERS Congress

News

moomoo

PinnedCONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS GOOD TOLERABILITY AND SAFETY SIMILAR TO PLACEBO

moomoo

PinnedCONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS QUICK AND LONG-LASTING EFFECTIVENESS IN PHASE 3 STUDY FOR ATOPIC DERMATITIS OVER 52 WEEKS

moomoo

PinnedCONNECT Biopharma Reports Encouraging Preliminary Results from Phase 1 Trial of Intravenous Rademikibart in Asthma and COPD Patients

Newsfilter

03-30Newsfilter

PinnedConnect Biopharma Secures $20.2 Million in Private Placement

NASDAQ.COM

03-30NASDAQ.COM

Connect Biopharma Reports Positive Clinical Data and Funding

NASDAQ.COM

03-30NASDAQ.COM

Connect Biopharma Reports Positive Phase 1 Results for Rademikibart

3 Analyst Rating

Wall Street analysts forecast CNTB stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.67

High

10.00

Current: 0.000

Low

7.00

Averages

8.67

High

10.00

BTIG

Buy

initiated

$10

AI Analysis

2025-10-31

Reason

BTIG

Price Target

$10

AI Analysis

2025-10-31

initiated

Buy

Reason

BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.

Northland

Outperform

initiated

$7.50

2025-07-22

Reason

Northland

Price Target

$7.50

2025-07-22

initiated

Outperform

Reason

Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB.O) is -1.96, compared to its 5-year average forward P/E of -3.48. For a more detailed relative valuation and DCF analysis to assess Connect Biopharma Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.48

Current PE

-1.96

Overvalued PE

-0.22

Undervalued PE

-6.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.30

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.06

Undervalued EV/EBITDA

-8.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

2103.63

Current PS

46251.92

Overvalued PS

11152.29

Undervalued PS

-6945.03

Financials

AI Analysis

Annual

Quarterly

Whales Holding CNTB

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Connect Biopharma Holdings Ltd (CNTB) stock price today?

The current price of CNTB is 2.83 USD — it has decreased -17.97

What is Connect Biopharma Holdings Ltd (CNTB)'s business?

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

What is the price predicton of CNTB Stock?

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Connect Biopharma Holdings Ltd (CNTB)'s revenue for the last quarter?

Connect Biopharma Holdings Ltd revenue for the last quarter amounts to 16.00K USD, decreased -98.69

What is Connect Biopharma Holdings Ltd (CNTB)'s earnings per share (EPS) for the last quarter?

Connect Biopharma Holdings Ltd. EPS for the last quarter amounts to -0.31 USD, increased 34.78

How many employees does Connect Biopharma Holdings Ltd (CNTB). have?

Connect Biopharma Holdings Ltd (CNTB) has 62 emplpoyees as of March 31 2026.

What is Connect Biopharma Holdings Ltd (CNTB) market cap?

Today CNTB has the market capitalization of 192.87M USD.